Jagsonpal Pharmaceuticals Allots Equity Shares Under Employee Stock Option Plan
Jagsonpal Pharmaceuticals Ltd announced the allotment of equity shares to its eligible employees under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022 (JPL ESOP 2022).The Company reported that its Nomination and Remuneration Committee issued and allotted 1,76,900 Equity Shares of Rs. 2/- each to employees upon the exercise of vested options.
This allotment represents a corporate action that increases the company’s paid-up share capital. Prior to the allotment, the paid-up share capital stood at Rs. 13,39,24,500, which constituted 6,69,62,250 equity shares of Rs. 2/- each.
Following the recent allotment, the paid-up share capital of the Company increased to Rs. 13,42,78,300. This revised capital now constitutes a total of 6,71,39,150 equity shares of Rs. 2/- each.
The allotted shares are stated to rank Pari-passu with the existing equity shares of the Company in all respects.
The transaction details, including the total issued capital after the issue, are summarized below:
| Metric | Before Allotment | After Allotment |
|---|---|---|
| Paid-up Share Capital | Rs. 13,39,24,500 | Rs. 13,42,78,300 |
| Number of Equity Shares | 6,69,62,250 | 6,71,39,150 |
| Share Face Value | Rs. 2/- | Rs. 2/- |
The document also noted that the shares issued under this plan rank pari passu with the existing shares, ensuring that the new shares are identical in all respects to the current shareholding.
JAGSNPHARM Stock Price Movement
Today, Jagsonpal Pharmaceuticals Limited shares edged higher to close at ₹194.62, posting a solid gain of 0.94% for the day. The equity saw significant trading action, staying within a range of ₹189.41 to ₹197.45 on a total volume of 132,210 shares.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.